EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database

Chikako Iwai, Taisuke Jo, Takaaki Konishi, Asahi Fujita, Nobuaki Michihata, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.04.012 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Chikako Iwai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Electronic address: chika88…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lung Diseases, Interstitial, ErbB Receptors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Library of the Ministry of Health, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: It is unclear whether the sequential administration of programmed death (PD)-1/programmed death-ligand 1 (PD-L1) inhibitors and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is associated with the development of severe interstitial pneumonitis (IP). PATIENTS AND METHODS: We identified 69,107 eligible patients with non-small cell lung cancer (NSCLC) from a Japanese national inpatient database, who initiated EGFR-TKI therapy. The study population was divided into the PD-1/PD-L1 inhibitor and non-prior PD-1/PD-L1 groups based on PD-1/PD-L1 administration before EGFR-TKI therapy. We conducted 1:4 matched-pair cohort analyses (n = 9,725) to compare the incidence of IP and in-hospital mortality within 90 days of administration of EGFR-TKI between the two groups after adjusting for the clinical background. Furthermore, we performed subgroup analyses categorized according to the duration of prior PD-1/PD-L1 inhibitor use. RESULTS: IP occurred in 4.4% of patients in the matched-pair cohort. PD-1/PD-L1 inhibitor-use before EGFR-TKI therapy was significantly associated with IP (odds ratio [OR], 1.79; 95% confidence interval [CI], 1.34-2.38) and in-hospital mortality (OR, 2.10; 95% CI, 1.72-2.55). Prior PD-1/PD-L1 inhibitor use in an interval of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsLung Diseases, InterstitialErbB ReceptorsProtein Kinase InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansMaleFemaleAgedMiddle AgedCohort StudiesDatabases, FactualAged, 80 and overJapanHospital MortalityMatched-Pair AnalysisTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

EGFR-TKIImmune checkpoint inhibitorNSCLCPD-1/PD-L1 inhibitor

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorPDCD1 protein, humanCD274 protein, humanImmune Checkpoint InhibitorsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. Electronic address: chika888i@m.u-tokyo.ac.jp.
  • Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan; Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.

Förderung

  • Library of the Ministry of Health
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Iwai, C., Jo, T., Konishi, T., Fujita, A., Michihata, N., Matsui, H., Fushimi, K., & Yasunaga, H. (2024). Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.04.012

Vancouver

Iwai C, Jo T, Konishi T, Fujita A, Michihata N, Matsui H, et al. Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.04.012

BibTeX
@article{Iwai2024,
  author = {Iwai, Chikako and Jo, Taisuke and Konishi, Takaaki and Fujita, Asahi and Michihata, Nobuaki and Matsui, Hiroki and Fushimi, Kiyohide and Yasunaga, Hideo},
  title = {Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.04.012}
}
Kostenlos starten →